Learnings From A Highly Diverse Observational Study Of 17,000+ Patients, Clinical Trial Surprises in 2024, and More
Clinical Leader
A resource and forum to investigate and resolve the common struggles related to running effective clinical trials.
Welcome to the Clinical Trial Insights newsletter, featuring strategic insights and expert opinions on designing and running clinical trials. Each edition covers the latest trending articles on ClinicalLeader.com.
In this week's issue, we'll review Agendia’s diverse, high-enrolling trial and how sponsor companies of investigational trials might benefit from its experiences, how AI could help us decipher the "language of biology" and streamline drug discovery, what stood out to clinical trial experts in 2024, how the clinical trial landscape for small cell lung cancer is evolving, and other popular insights.
If you like what you're seeing in our condensed LinkedIn editions, subscribe to our daily newsletter for full access to exclusive articles, webinars, e-books, and more! Subscribe Now →
WEBINAR 12.12.24
Personalized Medicine: Tailoring IRT/RTSM Solutions To Overcome Challenges
Discover how it’s possible to tailor RTSM to meet specific precision medicine challenges of expiry, visit & personalized shipment management during Perceptive Inc. 's webinar discussion on December 12th!
TOP 5 READS OF THE PAST WEEK
More than 17,000 patients have enrolled in Agendia ’s FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or III breast cancer. CMO William Audeh , MD, details Agendia ’s diverse, high-enrolling trial and how sponsor companies of investigational trials might benefit from its experiences.
With AI’s rapid advancements outpacing Moore’s Law, why hasn’t it dramatically improved the efficiency of pharmaceutical innovation? Dr. Tala Fakhouri explores how AI could help us decipher the "language of biology" and streamline drug discovery, while addressing the myths and challenges that regulatory bodies like the FDA must navigate.
Is it any surprise that when Chief Editor Dan Schell asked a group of clinical trial industry experts to summarize what stood out to them in 2024, that AI would be mentioned more than once? Probably not. Resistance to DCTs, increasing regulatory scrutiny, and a slowdown in CRO M&As also made their lists — but I’m guessing none of that surprises you, either.
The small cell lung cancer (SCLC) treatment landscape is advancing, particularly with immune checkpoint inhibitors and targeted therapies. Immunotherapies like pembrolizumab and novel antibody-drug conjugates are showing promising results in clinical trials. Explore the evolving landscape of SCLC through Novotech CRO's expert analysis.
We've overcomplicated site selection, says Stryde Research CEO Chintan Desai . Here, Desai details what qualities sponsors should really look for in sites and why some of our existing criteria aren't cutting it.
MORE TO EXPLORE
Clinical Leader is an online community serving professionals in the clinical research space. We share insights and best practices — from industry experts — to help sponsors and CROs tackle the biggest challenges they face in designing and running clinical trials.
To get the most out of our offerings, join the Clinical Leader community.
Clinical Quality Management Director at ProTrials Research, Creator of DID YOU KNOW...Information on Clinical Research Topics and Scenarios (on LinkedIn)
2moExcellent article and insights from the contributors in Were There Any Surprises In Clinical Trials In 2024? So many great takeaways!